Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression

Cell Death and Differentiation

Volumn 16, Issue 2, 2009, Pages 219-229

  Du, J ^a,b   Liang, X ^a   Liu, Y ^a   Qu, Z ^a   Gao, L ^a   Han, L ^a   Liu, S ^a   Cui, M ^a   Shi, Y ^a   Zhang, Z ^a   Yu, L ^c   Cao, L ^a,b   Ma, C ^a   Zhang, L ^a   Chen, Y ^d   Sun, W ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c Jinan Infectious Disease Hospital   (China)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HEPATITIS B VIRUS X PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DISEASE MODEL; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS GENOME;

ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HEPATITIS B VIRUS; HEPATITIS, CHRONIC; HEPATOCYTES; HUMANS; MICE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANS-ACTIVATORS; VIRAL CORE PROTEINS;

HEPATITIS B VIRUS;

EID: 58249123434     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2008.144     Document Type: Article

References (39)

1. Beasley RP, Hwang LY, Lin CC, Chien CS. A prospective study of 22 707 men in Taiwan Hepatocellular carcinoma and hepatitis B virus. Lancet 1981; 2: 1129-1133.
2. Liu DX. A new hypothesis of pathogenetic mechanism of viral hepatitis B and C. Med Hypotheses 2001; 56: 405-408.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK S et al Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
4. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.
5. Liang X, Liu Y, Zhang Q, Gao L, Han L, Ma C et al. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 2007; 178: 503-510.
6. Liu YG, Liu SX, Liang XH, Zhang Q, Gao LF, Han LH et al. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem Biophys Res Commun 2007; 352: 329-334.
7. Liang X, Du J, Liu Y, Cui M, Ma C, Han L et al. The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis 2007; 12: 1827-1836.
8. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998; 424: 41-45.
9. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997; 416: 329-334.
10. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999; 59: 2770-2775.
11. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D et al. Identification of a new murine TNF receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2002; 278: 5444-5454.
12. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
13. Kwon JA, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells. Biol Chem 2003; 384: 203-212.
14. Kim JH, Kang S, Kim J, Ahn BY. Hepatitis B virus core protein stimulates the proteasome-mediated degradation of viral x protein. J Virol 2003; 77: 7166-7173.
15. Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAILR1/ death receptor 4 expression. J Hepatol 2003; 39: 414-420.
16. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 2002; 16: 33-45.
17. Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567.
18. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
19. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
20. Hao C, Song JH, his B, Lewis J, Song DK, Petruk KC et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64: 8502-8506.
21. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2 L/ TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
22. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC et al Temperature-sensitive differential affinity of TRAIL for its receptors DR5 is the highest affinity receptor. J Biol Chem 2000; 275: 23319-23325.
23. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-2212.
24. Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JJ. Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ 2002; 9: 274-286.
25. Tanaka F, Kawakami A, Tamai M, Nakamura H, Iwanaga N, Izumi Y et al IFN-gamma/ JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: Novel finding of cycloheximide-regulating death receptor expression. Int J Mol Med 2005; 15: 833-839.
26. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002; 34 114-122.
27. Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C et al. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: Overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005; 11: 8585-8591.
28. Mondelli M, Tedder RS, Ferns B, Pontisso P, Realdi G, Alberti A. Differential distribution of hepatitis B core and E antigens in hepatocytes: Analysis by monoclonal antibodies. Hepatology 1986; 6: 199-204.
29. Eckhardt SG, Milich DR, McLachlan A. Hepatitis B virus core antigen has two nuclear localization sequences in the arginine-rich carboxyl terminus. J Virol 1991; 65: 575-582.
30. Hatton T, Zhou S, Standring DN. RNA- and DNA-binding activities in hepatitis B virus capsid protein: A model for their roles in viral replication. J Virol 1992; 66: 5232-5241.
31. Liao W, Ou JH. Phosphorylation and nuclear localization of the hepatitis B virus core protein: Significance of serine in the three repeated SPRRR motifs. J Virol 1995; 69: 1025-1029.
32. Whitten TM, Quets AT, Schloemer RH. Dentification of the hepatitis B virus factor that inhibits expression of the b interferon gene. J virol 1991; 65: 4699-4704.
33. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G et al Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404-5416.
34. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19: 1735-1743.
35. Burns TF, Bernhard EJ, El-Deiry WS. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20: 4601-4612.
36. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001; 507: 381-385.
37. Barone M, Maiorano E, Ladisa R, Cuomo R, Pece A, Berloco P et al. Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice. Hepatology 2003; 37: 880-886.
38. Billaud JN, Peterson D, Lee BO, Maruyama T, Chen A, Sallberg M et al Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 2007; 25: 1593-1606.
39. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.